Utilization of an optimized AlphaFold protein model for structure‐based design of a selective HDAC11 inhibitor with anti‐neuroblastoma activity
Open Access
- 12 July 2024
- journal article
- research article
- Published by Wiley in Archiv der Pharmazie
- Vol. 357 (10) , e2400486
Abstract
AlphaFold is an artificial intelligence approach for predicting the three‐dimensional (3D) structures of proteins with atomic accuracy. One challenge that limits the use of AlphaFold models for drug discovery is the correct prediction of folding in the absence of ligands and cofactors, which compromises their direct use. We have previously described the optimization and use of the histone deacetylase 11 (HDAC11) AlphaFold model for the docking of selective inhibitors such as FT895 and SIS17. Based on the predicted binding mode of FT895 in the optimized HDAC11 AlphaFold model, a new scaffold for HDAC11 inhibitors was designed, and the resulting compounds were tested in vitro against various HDAC isoforms. Compound 5a proved to be the most active compound with an IC50 of 365 nM and was able to selectively inhibit HDAC11. Furthermore, docking of 5a showed a binding mode comparable to FT895 but could not adopt any reasonable poses in other HDAC isoforms. We further supported the docking results with molecular dynamics simulations that confirmed the predicted binding mode. 5a also showed promising activity with an EC50 of 3.6 µM on neuroblastoma cells.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Discovery of novel and selective SIK2 inhibitors by the application of AlphaFold structures and generative modelsBioorganic & Medicinal Chemistry, 2023
- Evaluation of AlphaFold2 structures as docking targetsProtein Science, 2022
- HDAC11: a rising star in epigeneticsBiomedicine & Pharmacotherapy, 2020
- Structural Biology of Epigenetic Targets: Exploiting Complexity2019
- Histone deacetylase 11 suppresses p53 expression in pituitary tumor cellsCell Biology International, 2017
- Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichmentsJournal of Computer-Aided Molecular Design, 2013
- HDAC11 is a novel drug target in carcinomasInternational Journal of Cancer, 2012
- Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitorsBioorganic & Medicinal Chemistry, 2011
- Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solutionJournal of Computer-Aided Molecular Design, 2010
- Epik: a software program for pK a prediction and protonation state generation for drug-like moleculesJournal of Computer-Aided Molecular Design, 2007